Skip to main content

Table 1 Clinicopathological features of 378 patients who were treated with preoperative chemotherapy

From: Clinical verification of body mass index and tumor immune response in patients with breast cancer receiving preoperative chemotherapy

Parameters (n = 378) Number of patients (%)
Age (years old) 56 (24–78)
Tumor size (mm) 28.7 (9.2–119.8)
Skin infiltration Negative / Positive 318 (84.1%) / 60 (15.9%)
Lymph node metastasis N0 / N1 / N2 / N3 132 (34.9%) / 140 (37.0%) / 71 (18.8%) / 35 (9.3%)
Estrogen receptor Negative / Positive 223 (59.0%) / 155 (41.0%)
Progesterone receptor Negative / Positive 301 (79.6%) / 77 (20.4%)
HER2 Negative / Positive 238 (63.0%) / 140 (37.0%)
Ki67 ≤ 14% / > 14% 121 (32.0%) / 257 (68.0%)
Intrinsic subtype HRBC / HER2BC / TNBC 159 (42.1%) / 93 (24.6%) / 126 (33.3%)
Objective response rate Non-Responders / Responders 41 (10.8%) / 337 (89.2%)
Pathological response Non-pCR / pCR 250 (66.1%) / 128 (33.9%)
TILs Low / High 209 (55.3%) / 169 (44.7%)
Body mass index (kg/m2) 21.9 (14.3–38.5)
Body mass index categorized Underweight / Normal / Overweight / Obese 49 (13.0%) / 244 (64.5%) / 66 (17.5%) / 19 (5.0%)
  1. HER: human epidermal growth factor receptor. HRBC: hormone receptor-positive breast cancer (ER+ and/or PgR+). HER2BC: human epidermal growth factor receptor 2-enriched breast cancer (ER-, PgR-, and HER2+). TNBC: triple negative breast cancer (ER-, PgR-, and HER2-). pCR: pathological complete response. TILs: tumor-infiltrating lymphocytes